(Co. Reg. No: 200405621W)

NEWS RELEASE

iX Biopharma Raises S$6.7 Million to Accelerate U.S. Expansion

- ✓ **34% higher than the initial S$5.0m target, following strong demand**
- ✓ **Institutional participation from Lion Global Investors Limited (a member of the OCBC Group) and Ginko-AGT Global Growth Fund**

SINGAPORE, 31 October 2025 — iX Biopharma Ltd. (SGX: 42C) ("iX Biopharma" or "the Company") has completed its upsized share placement, raising S$6.7 million after demand exceeded the original S$5.0 million target. The Company issued 67,000,000 new shares at S$0.10 each. Investors include prominent funds like Lion Global Investors Limited (as investment manager for clients) and Ginko-AGT Global Growth Fund. OCBC Bank acted as Placement Agent.

Eva Tan, Chief Commercial Officer of the Company, said: "The placement demand is a strong endorsement of our strategy to expand into the U.S. through compounding pharmacies, a model that allows immediate commercialisation of our novel sublingual products without further R&D investment. It reflects investors' confidence in our turnaround and gives us the resources to scale."

The entry into the U.S. market gives iX Biopharma access to the world's largest healthcare market. The Company will focus on its compounding and wellness businesses, anchored by its market-leading SL-NAD+ and other products that support longevity and healthspan. Alongside its drug development division, these three pillars form the foundation for iX Biopharma's next phase of growth.

This media release should be read together with the Company's SGXNET announcements dated 28 October 2025, 30 October 2025 and 31 October 2025 relating to the Placement.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Daniel Chow
Director of Business Development
T: +65 6235 2270
E: daniel.chow@ixbiopharma.com